Genotyping Market Size, Share & Trends Analysis Report By Technology (PCR, Capillary Electrophoresis, Microarrays, Sequencing, Mass Spectrometry), By Product, By Application, By End-use, By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global genotyping market was valued at USD 12.65 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 15.6% from 2022 to 2030. The growth can be attributed to technological advancements, the rising prevalence of cancer & genetic disorders, and increasing R&D funding for precision medicine research. Furthermore, the COVID-19 pandemic witnessed a positive impact on the genotyping market, as the pandemic led to an increased demand for COVID-19 genotyping kits. SNP genotyping has been used for the detection of genetic variants of the Covid-19 virus.

An increase in government funding, especially for genomic research, by government bodies and pharma & biotechnology companies to accelerate research is expected to drive the genotyping market. For instance, in September 2018, NIH granted USD 28.6 million to the “All of Us Research Program” for establishing three genome centers around the U.S. dedicated to precision medicine research.

The prevalence of chronic diseases, such as cancer and genetic disease, is increasing worldwide and is expected to drive demand for genotypic-based diagnostic testing. For instance, according to WHO, 19.1 million new cancer cases were diagnosed globally in 2020. Cancer-causing viruses such as Human Papilloma Virus (HPV) and Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV) are also responsible for about 20% of cancer deaths worldwide. The number of cancer cases is expected to increase by around 70% over the next two decades, estimated based on population growth and aging. Therefore, the rising prevalence of cancer is expected to be a high-impact rendering driver of this market.

However, a lack of skilled technicians, especially in developing countries, could slow the market growth, as genotyping data analysis and management require a high level of technical expertise. At the moment, developing nations have a relatively low number of professionals and experts. 

Strategic initiatives undertaken by local players are anticipated to contribute to market growth. For instance, in February 2021, VG Acquisition Corp. merged with 23andMe, a U.S.-based genetics and research company actively working with direct-to-consumer genotyping solutions. This merger would provide capital funds for their genetic consumer health business.

Product Insights

The reagents & kits segment held the largest share in 2021. It is expected to expand at a CAGR of 15.8% during the forecast years. This is due to the increasing demand for genetic testing, rising investments in R&D, and increasing genotyping testing volumes. Furthermore,  the software & services segment is also anticipated to expand at a significant rate due to the rise in the adoption of software-based services by research laboratories and academic institutions. Bioinformatics solution improves the efficacy of sequencing methods and helps avoid errors that occur in traditional sequencing methods. These services find application in agrigenomics, human diseases, animal livestock, and microbes. All the aforementioned factors are anticipated to propel market growth over the forecast period.

Application Insights

Pharmacogenomics is expected to be the fastest-growing technology during the forecast period. Genotyping helps identify patients suitable for a particular drug based on the patients’ genetic makeup. Identifying population subsets that are responsive or non-responsive help deliver tailor-made treatment to these individuals with different genetic makeup and helps reduce clinical trial attrition. Moreover, key players play an active role by providing solutions for pharmacogenomics studies. For instance, RT PCR solution by Thermo Fisher Scientific for pharmacogenomic testing includes TaqMan assays and QuantStudio instruments. It also provides a PharmacoScan solution with a PharmacoScan Assay Kit.

Diagnostics and personalized medicine account for the highest share in genotyping market, owing to the rising adoption of genotyping products for research and the increasing need for the diagnosis of genetic diseases. In addition, strategic collaborations among players are expected to boost the market growth. For instance, in February 2019, Centogene entered into a strategic partnership with Sarepta Therapeutics, Inc., to diagnose Duchenne muscular dystrophy patients in the MENA region.

Technology Insights

PCR segment dominated the market and accounted for the largest revenue share in 2021. This high market share is attributable to increasing demand for advanced diagnostic techniques, rising number of CROs, forensic & research laboratories, and growing prevalence of diseases such as chronic diseases & genetic disorders are major factors expected to drive market growth.

Moreover, sequencing is expected to expand at a lucrative rate during the forecast period due to improved specificity and better ability to detect low expression & differentially expressed genes than other techniques. Genotyping by sequencing also helps perform comparative analysis across samples without the need for a reference genome.

End-use Insights

The diagnostics and research laboratories segment is expected to expand at the fastest CAGR rate during the forecast period, owing to the rising adoption of genotyping products for research and the increasing need for diagnosis of genetic diseases & cancer. In addition, the growing prevalence of cancer also increases the demand for diagnostic tests, such as cancer genotyping assays, which is expected to drive the market.

The biopharmaceutical and pharmaceutical companies segment is expected to expand at a CAGR of 15.9% during the forecast period. The growing need for pharmacogenomics in the drug development process and FDA recommendations to include pharmacogenomics studies & genotyping in the drug discovery process are factors expected to drive market growth. Companies actively use pharmacogenomics to develop novel drugs. For instance, Pfizer is conducting a genotyping-based clinical trial to study the efficacy of Talazoparib in patients with somatic BRCA mutant resistant metastatic breast cancer.  Thus, the rising number of clinical trials based on pharmacogenomics is expected to drive segment growth.

Regional Insights 

North America accounted for the largest market share in 2021, owing to the increasing adoption of technologically advanced products, the presence of major pharmaceutical & biopharmaceutical companies, proactive government measures, and advances in healthcare infrastructure. The presence of major players in this region is another key factor responsible for high market share.

Europe is also anticipated to exhibit a CAGR of 17.0% during the forecast period. The presence of enormous untapped growth can be attributed to several factors, such as technological advancements and the growing pharma and biopharma sector in the region. The Asia Pacific is anticipated to exhibit the fastest opportunities, and an increasing number of clinical trials are being conducted in this region.

Key Companies & Market Share Insights

Key players are adopting strategies, such as partnerships and new product launches to retain market share. For instance, in January 2020, Illumina and Roche collaborated to improve patient access to oncology genomic testing. Furthermore, in September 2021, Illumina under its Illumina Accelerator program invested in seven genomics companies across various countries.

Some of the prominent players in the global genotyping market include:

• Illumina Inc.

• Thermo Fisher Scientific Inc.

• Qiagen Inc.

• F. Hoffmann-La Roche Ltd.

• Fluidigm Corporation

• Danaher Corporation

• Agilent Technologies

• Eurofins Scientific Inc.

• GE Healthcare Inc.

• Bio-Rad Laboratories Inc.

Genotyping Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global genotyping market report based on product, technology, application, end-use, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Instruments

    • Sequencers & Amplifiers

    • Analyzers

  • Reagents & Kits

  • Software and Services

  • Genotyping Services

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Pharmacogenomics

  • Diagnostics and Personalized Medicine

  • Agricultural Biotechnology

  • Animal Genetics

  • Others

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • PCR

    • Real-time PCR

    • Digital PCR

  • Capillary Electrophoresis

    • Amplified Fragment Length Polymorphism

    • Restriction Fragment Length Polymorphism

    • Single-Strand Conformation Polymorphism

  • Microarrays

    • DNA Microarrays

    • Peptide Microarrays

    • Others

  • Sequencing

    • Next Generation Sequencing

    • Pyro Sequencing

    • Sanger Sequencing

  • Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-TOF) Mass Spectroscopy

  • Others

• End-Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Pharmaceutical And Biopharmaceutical Companies

  • Diagnostics And Research Laboratories

  • Academic Institutes

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

  • Asia Pacific

    • China

    • India

    • Japan

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE